sb 203580 has been researched along with 2-piperidone in 2 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (2-piperidone) | Trials (2-piperidone) | Recent Studies (post-2010) (2-piperidone) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 1,305 | 65 | 594 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, Y; Fu, H; Khuri, FR; Li, Z; Liotta, D; Lou, B; Purcell, J; Snyder, JP; Thomas, SL; Zhao, J | 1 |
| Hsieh, YH; Li, GC; Lin, RC; Lin, YC; Lu, KH; Wu, HH; Yang, JS; Yang, SF | 1 |
2 other study(ies) available for sb 203580 and 2-piperidone
| Article | Year |
|---|---|
Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy.
Topics: Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Cell Line, Tumor; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; MAP Kinase Signaling System; p38 Mitogen-Activated Protein Kinases; Piperidones; Pyridines | 2010 |
CLEFMA Activates the Extrinsic and Intrinsic Apoptotic Processes through JNK1/2 and p38 Pathways in Human Osteosarcoma Cells.
Topics: Apoptosis; Benzylidene Compounds; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Osteosarcoma; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperidones; Pyridines; Signal Transduction | 2019 |